Cargando…

Pluripotent stem cells in neuropsychiatric disorders

Neuropsychiatric disorders place an enormous medical burden on patients across all social and economic ranks. The current understanding of the molecular and cellular causes of neuropsychiatric disease remains limited, which leads to a lack of targeted therapies. Human-induced pluripotent stem cell (...

Descripción completa

Detalles Bibliográficos
Autores principales: Soliman, M A, Aboharb, F, Zeltner, N, Studer, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582162/
https://www.ncbi.nlm.nih.gov/pubmed/28322279
http://dx.doi.org/10.1038/mp.2017.40
_version_ 1783261135664840704
author Soliman, M A
Aboharb, F
Zeltner, N
Studer, L
author_facet Soliman, M A
Aboharb, F
Zeltner, N
Studer, L
author_sort Soliman, M A
collection PubMed
description Neuropsychiatric disorders place an enormous medical burden on patients across all social and economic ranks. The current understanding of the molecular and cellular causes of neuropsychiatric disease remains limited, which leads to a lack of targeted therapies. Human-induced pluripotent stem cell (iPSC) technology offers a novel platform for modeling the genetic contribution to mental disorders and yields access to patient-specific cells for drug discovery and personalized medicine. Here, we review recent progress in using iPSC technology to model and potentially treat neuropsychiatric disorders by focusing on the most prevalent conditions in psychiatry, including depression, anxiety disorders, bipolar disorder and schizophrenia.
format Online
Article
Text
id pubmed-5582162
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55821622017-09-06 Pluripotent stem cells in neuropsychiatric disorders Soliman, M A Aboharb, F Zeltner, N Studer, L Mol Psychiatry Review Neuropsychiatric disorders place an enormous medical burden on patients across all social and economic ranks. The current understanding of the molecular and cellular causes of neuropsychiatric disease remains limited, which leads to a lack of targeted therapies. Human-induced pluripotent stem cell (iPSC) technology offers a novel platform for modeling the genetic contribution to mental disorders and yields access to patient-specific cells for drug discovery and personalized medicine. Here, we review recent progress in using iPSC technology to model and potentially treat neuropsychiatric disorders by focusing on the most prevalent conditions in psychiatry, including depression, anxiety disorders, bipolar disorder and schizophrenia. Nature Publishing Group 2017-09 2017-03-21 /pmc/articles/PMC5582162/ /pubmed/28322279 http://dx.doi.org/10.1038/mp.2017.40 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Review
Soliman, M A
Aboharb, F
Zeltner, N
Studer, L
Pluripotent stem cells in neuropsychiatric disorders
title Pluripotent stem cells in neuropsychiatric disorders
title_full Pluripotent stem cells in neuropsychiatric disorders
title_fullStr Pluripotent stem cells in neuropsychiatric disorders
title_full_unstemmed Pluripotent stem cells in neuropsychiatric disorders
title_short Pluripotent stem cells in neuropsychiatric disorders
title_sort pluripotent stem cells in neuropsychiatric disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582162/
https://www.ncbi.nlm.nih.gov/pubmed/28322279
http://dx.doi.org/10.1038/mp.2017.40
work_keys_str_mv AT solimanma pluripotentstemcellsinneuropsychiatricdisorders
AT aboharbf pluripotentstemcellsinneuropsychiatricdisorders
AT zeltnern pluripotentstemcellsinneuropsychiatricdisorders
AT studerl pluripotentstemcellsinneuropsychiatricdisorders